Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low on Analyst Downgrade

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares hit a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to $1,000.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Regeneron Pharmaceuticals traded as low as $618.51 and last traded at $630.08, with a volume of 111538 shares changing hands. The stock had previously closed at $637.36.

Several other equities analysts have also commented on REGN. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Bank of America reiterated an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $966.88.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. DSG Capital Advisors LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $603,000. 111 Capital purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $378,000. NorthCrest Asset Manangement LLC boosted its position in shares of Regeneron Pharmaceuticals by 2.4% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 11,346 shares of the biopharmaceutical company’s stock worth $8,082,000 after acquiring an additional 270 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $29,656,000. Finally, PKO Investment Management Joint Stock Co purchased a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $7,693,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.2 %

The stock has a market cap of $69.52 billion, a price-to-earnings ratio of 16.61, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The firm’s 50-day moving average is $683.88 and its 200 day moving average is $795.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the firm posted $11.86 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.